

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1-55 (canceled)

56. (currently amended) A method for ~~inhibiting~~ modulating angiogenesis in a mammal comprising administering an antibody or antigen binding fragment thereof that specifically binds a polypeptide comprising an amino acid sequence of SEQ ID NO:76 or an immunogenic fragment of a protein comprising an amino acid sequence of SEQ ID NO:76 to the mammal. ~~a therapeutically effective amount of a therapeutic composition that inhibits angiogenesis.~~

57-68 (canceled)

69. (new) The method of claim 56, wherein the polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:75.

70. (new) The method of claim 56, wherein said antibody is a polyclonal, monoclonal antibody, antibody fragments, human, humanized, chimeric, bispecific or heterconjugate antibody.

71. (new) The method of claim 70, wherein said antibody is an antagonist or neutralizing antibody.

72. (new) The method of claim 56, wherein the antibody has polypeptopic specificity.

73. (new) The method of claim 56, wherein the antibody is a human, chimeric, or humanized antibody.

74. (new)      The method of claim 56, wherein the antibody is an antibody fragment.
75. (new)      The method of claim 74, wherein the antibody fragment comprises a Fab fragment, Fab' fragment, F(ab')<sub>2</sub> fragment, or Fv fragment.
76. (new)      The method of claim 56, wherein the antibody is a heteroconjugate antibody.